196 related articles for article (PubMed ID: 36457968)
1. 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.
Banach M; Reiner Z; Cicero AFG; Sabouret P; Viigimaa M; Sahebkar A; Postadzhiyan A; Gaita D; Pella D; Penson PE
Arch Med Sci; 2022; 18(6):1429-1434. PubMed ID: 36457968
[No Abstract] [Full Text] [Related]
2. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
3. The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering.
Pencina MJ; Pencina KM; Lloyd-Jones D; Catapano AL; Thanassoulis G; Sniderman AD
Circulation; 2020 Sep; 142(9):827-837. PubMed ID: 32700572
[TBL] [Abstract][Full Text] [Related]
4. Effect of Ezetimibe + Pitavastatin on Cardiovascular Outcomes in Patients with ST-Segment Elevation Myocardial Infarction (from the HIJ-PROPER Study).
Otsuki H; Arashi H; Yamaguchi J; Kawada-Watanabe E; Ogawa H; Hagiwara N
Am J Cardiol; 2020 Oct; 132():15-21. PubMed ID: 32773226
[TBL] [Abstract][Full Text] [Related]
5. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
7. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.
Hsu HY; Lin CJ; Lee YS; Wu TH; Chien KL
BMC Cardiovasc Disord; 2020 Jul; 20(1):334. PubMed ID: 32660417
[TBL] [Abstract][Full Text] [Related]
9. Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy.
Masana L; Ibarretxe D; Plana N
Curr Cardiol Rep; 2020 Jun; 22(8):66. PubMed ID: 32562015
[TBL] [Abstract][Full Text] [Related]
10. Drug treatment of hyperlipidemia in women.
Walsh JM; Pignone M
JAMA; 2004 May; 291(18):2243-52. PubMed ID: 15138247
[TBL] [Abstract][Full Text] [Related]
11. Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.
Stefanutti C; Julius U; Watts GF; Harada-Shiba M; Cossu M; Schettler VJ; De Silvestro G; Soran H; Van Lennep JR; Pisciotta L; Klör HU; Widhalm K; Moriarty PM;
J Clin Lipidol; 2017; 11(4):858-871.e3. PubMed ID: 28572002
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on low-density lipoprotein cholesterol goal achievement.
Catapano AL
Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK.
Danese M; Sidelnikov E; Villa G; Catterick D; Iqbal M; Gleeson M; Lubeck D; Patel J
BMJ Open; 2022 Apr; 12(4):e055015. PubMed ID: 35487737
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering for peripheral arterial disease of the lower limb.
Aung PP; Maxwell HG; Jepson RG; Price JF; Leng GC
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD000123. PubMed ID: 17943736
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering therapy in people with type 2 diabetes.
Colagiuri S; Best J
Curr Opin Lipidol; 2002 Dec; 13(6):617-23. PubMed ID: 12441885
[TBL] [Abstract][Full Text] [Related]
16. Impact of lipid-lowering therapies on cardiovascular outcomes according to coronary artery calcium score. A systematic review and meta-analysis.
Gallone G; Elia E; Bruno F; Angelini F; Franchin L; Bocchino PP; Piroli F; Annone U; Montabone A; Marengo G; Bertaina M; De Filippo O; Baldetti L; Palmisano A; Serafini A; Esposito A; Depaoli A; D'ascenzo F; Fonio P; De Ferrari GM
Rev Esp Cardiol (Engl Ed); 2022 Jun; 75(6):506-514. PubMed ID: 34483065
[TBL] [Abstract][Full Text] [Related]
17. Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study.
Bittencourt MS; Blankstein R; Blaha MJ; Sandfort V; Agatston AS; Budoff MJ; Blumenthal RS; Krumholz HM; Nasir K
Eur J Prev Cardiol; 2018 Nov; 25(17):1887-1898. PubMed ID: 30043629
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review.
Masson W; Corral P; Barbagelata L; Lavalle-Cobo A; Nogueira JP; Siniawski D; Ray KK
J Clin Lipidol; 2022; 16(5):562-573. PubMed ID: 35918256
[TBL] [Abstract][Full Text] [Related]
19. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
20. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
